AAAAAA
Results:
1-18
|
Results: 18
Authors:
Ko, YJ
Small, EJ
Kabbinavar, F
Chachoua, A
Taneja, S
Reese, D
DePaoli, A
Hannah, A
Balk, SP
Bubley, GJ
Citation: Yj. Ko et al., A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer, CLIN CANC R, 7(4), 2001, pp. 800-805
Authors:
Taplin, ME
Bubley, GJ
Rajeshkumar, B
Shuster, T
Ko, YJ
Morganstern, DE
Citation: Me. Taplin et al., Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer, SEMIN ONCOL, 28(4), 2001, pp. 32-39
Authors:
Bubley, GJ
Citation: Gj. Bubley, Is the flare phenomenon clinically significant?, UROLOGY, 58(2A), 2001, pp. 5-9
Authors:
Fair, WR
Trachtenberg, J
Bubley, GJ
Heston, WD
Peehl, DM
Newling, DWW
Citation: Wr. Fair et al., Discussion following Dr. William R. Fair's presentation of Dr. Paul F. Schellhammer's paper, UROLOGY, 58(2A), 2001, pp. 15-15
Authors:
Fair, WR
Stricker, HJ
Lieberman, R
Bubley, GJ
Trachtenberg, J
Heston, WDW
Citation: Wr. Fair et al., Discussion following Dr. Hans J. Stricker's presentations, UROLOGY, 58(2A), 2001, pp. 27-27
Authors:
Daniell, HW
Chen, S
Fair, WR
Heston, WDW
Pirani, JF
Bubley, GJ
Carroll, PR
Gleave, ME
Citation: Hw. Daniell et al., Discussion following Dr. Sophie Chen's (pages 28-35) and Dr. John F. Pirani's presentations, UROLOGY, 58(2A), 2001, pp. 38-38
Authors:
Lieberman, R
Gleave, ME
Carroll, PR
Bubley, GJ
Citation: R. Lieberman et al., Discussion following Dr. Martin E. Gleave's presentation, UROLOGY, 58(2A), 2001, pp. 48-49
Authors:
Trachtenberg, J
Grossfeld, GD
Lubeck, DP
Bubley, GJ
Carroll, PR
Fair, WR
Newling, DWW
Citation: J. Trachtenberg et al., Discussion following Dr. Gary D. Grossfeld's presentation, UROLOGY, 58(2A), 2001, pp. 64-64
Authors:
Carroll, PR
D'Amico, A
Malkowicz, SB
Gleave, ME
Bubley, GJ
Citation: Pr. Carroll et al., Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 82-82
Authors:
Stanbrough, M
Leav, I
Kwan, PWL
Bubley, GJ
Balk, SP
Citation: M. Stanbrough et al., Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium, P NAS US, 98(19), 2001, pp. 10823-10828
Authors:
Jones, GB
Hynd, G
Wright, JM
Purohit, A
Plourde, GW
Huber, RS
Mathews, JE
Li, AW
Kilgore, MW
Bubley, GJ
Yancisin, M
Brown, MA
Citation: Gb. Jones et al., Target-directed enediynes: Designed estramycins, J ORG CHEM, 66(11), 2001, pp. 3688-3695
Authors:
Ali Tahir, SM
Cheng, O
Shaulov, A
Koezuka, Y
Bubley, GJ
Wilson, SB
Balk, SP
Exley, MA
Citation: Sm. Ali Tahir et al., Loss of IFN-gamma production by invariant NK T cells in advanced cancer, J IMMUNOL, 167(7), 2001, pp. 4046-4050
Authors:
Eder, JP
Kantoff, PW
Roper, K
Xu, GX
Bubley, GJ
Boyden, J
Gritz, L
Mazzara, G
Oh, WK
Arlen, P
Tsang, KY
Panicali, D
Schlom, J
Kufe, DW
Citation: Jp. Eder et al., A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer, CLIN CANC R, 6(5), 2000, pp. 1632-1638
Authors:
Jones, GB
Mitchell, MO
Weinberg, JS
D'Amico, AV
Bubley, GJ
Citation: Gb. Jones et al., Towards enzyme activated antiprostatic agents, BIOORG MED, 10(17), 2000, pp. 1987-1989
Authors:
Bubley, GJ
Carducci, M
Dahut, W
Dawson, N
Daliani, D
Eisenberger, M
Figg, WD
Freidlin, B
Halabi, S
Hudes, G
Hussain, M
Kaplan, R
Myers, C
Oh, W
Petrylak, DP
Reed, E
Roth, B
Sartor, O
Scher, H
Simons, J
Sinibaldi, V
Small, EJ
Smith, MR
Trump, DL
Vollmer, R
Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
Authors:
Taplin, ME
Bubley, GJ
Ko, YJ
Small, EJ
Upton, M
Rajeshkumar, B
Balk, SP
Citation: Me. Taplin et al., Selection for androgen receptor mutations in prostate cancers treated withandrogen antagonist, CANCER RES, 59(11), 1999, pp. 2511-2515
Authors:
Cenni, B
Kim, HK
Bubley, GJ
Aebi, S
Fink, D
Teicher, BA
Howell, S
Christen, RD
Citation: B. Cenni et al., Loss of DNA mismatch repair facilitates reactivation of a reporter plasmiddamaged by cisplatin, BR J CANC, 80(5-6), 1999, pp. 699-704
Authors:
Chott, A
Sun, Z
Morganstern, D
Pan, J
Li, T
Susani, M
Mosberger, I
Upton, MP
Bubley, GJ
Balk, SP
Citation: A. Chott et al., Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor, AM J PATH, 155(4), 1999, pp. 1271-1279
Risultati:
1-18
|